Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 1/20 | 0.62 |
| ▸ | TGM2 | P21980 | 1/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.55 |
| ▸ | KRAS | P01116 | 8/20 | 0.55 |
| ▸ | IMPDH2 | P12268 | 6/20 | 0.55 |
| ▸ | IMPDH1 | P20839 | 2/20 | 0.55 |
| ▸ | HINT1 | P49773 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.53 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.53 |
| ▸ | FUT5 | Q11128 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL21715317 | 0.89 | NT5E (0.69) | NT5ETGM2KRASIMPDH2IMPDH1 | |
| SCHEMBL21742888 | 0.88 | NT5E (0.70) | NT5ETGM2KRASIMPDH2IMPDH1 | |
| E626 SCHEMBL2775605 | 0.87 | NT5E (0.77) | NT5ETGM2KRASIMPDH2IMPDH1 | |
| SCHEMBL21742747 | 0.87 | KRAS (0.72) | NT5ETGM2KRASFUT5 | |
| Guanosine SCHEMBL22134208 | 0.86 | NT5E (0.69) | NT5ETGM2HPGDKRASIMPDH2 | |
| E626 SCHEMBL3735436 | 0.86 | NT5E (0.76) | NT5ETGM2KRASIMPDH2IMPDH1 | |
| Guanosine SCHEMBL27797461 | 0.86 | NT5E (0.70) | NT5ETGM2HPGDKRASIMPDH2 | |
| Guanosine SCHEMBL37404 | 0.86 | NT5E (0.70) | NT5ETGM2HPGDKRASIMPDH2 | |
| Guanosine SCHEMBL44407 | 0.85 | NT5E (0.72) | NT5ETGM2HPGDKRASHINT1 | |
| Guanosine SCHEMBL2589323 | 0.85 | NT5E (0.72) | NT5ETGM2HPGDKRASHINT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10696709-B2 | Phosphotriazole MRNA 5′-end cap analogs, composition comprising the same, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule, protein or peptide | UNIWERSYTET WARSZAWSKI (PL) | 2020-06-30 | — | — | US | disclosed |
| EP-3484907-B1 | NOVEL PHOSPHOTRIAZOLE MRNA 5'-END CAP ANALOGS, COMPOSITION COMPRISING THE SAME, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE, PROTEIN OR PEPTIDE | UNIV WARSZAWSKI (PL) | 2020-05-13 | — | — | EP | disclosed |
| US-20200055891-A1 | NOVEL PHOSPHOTRIAZOLE MRNA 5'-END CAP ANALOGS, COMPOSITION COMPRISING THE SAME, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE, PROTEIN OR PEPTIDE | UNIWERSYTET WARSZAWSKI (PL) | 2020-02-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10696709-B2 | Phosphotriazole MRNA 5′-end cap analogs, composition comprising the same, RNA molecule incorporating the same, uses thereof and method of synthesizing RNA molecule, protein or peptide | RNGTT, RNMT, NSUN3 | NT5E 1027/4885TGM2 3265/4885HPGD 4480/4885 |
| US-20200055891-A1 | NOVEL PHOSPHOTRIAZOLE MRNA 5'-END CAP ANALOGS, COMPOSITION COMPRISING THE SAME, RNA MOLECULE INCORPORATING THE SAME, USES THEREOF AND METHOD OF SYNTHESIZING RNA MOLECULE, PROTEIN OR PEPTIDE | RNGTT, RNMT, NSUN3 | NT5E 867/4885TGM2 3588/4885HPGD 4544/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.